Literature DB >> 17089085

Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patients.

Ali Hamaad1, W Kaeng Lee, Gregory Y H Lip, Robert J MacFadyen.   

Abstract

OBJECTIVE: To determine the effects of n3-PUFA supplementation, in the dose used in the GISSI-Prevenzione study, on indices of heart rate variability (HRV) in patients following myocardial infarction (AMI).
MATERIALS AND METHODS: Open label randomised single blind controlled trial. Thirty eight patients post AMI, stable on standard secondary prevention drug therapy were single blind randomised to receive either Omacor 1 g/day (n = 21) or usual care (n = 17). HRV indices (time and frequency-domain) were measured at baseline and following 3 months of treatment.
RESULTS: At baseline there were no significant differences in clinical, biochemical or HRV indices between patient groups. After 3 months therapy there were no observed changes in measured HRV indices in either the Omacor supplemented or 'usual care' groups.
CONCLUSIONS: Three month supplementation of omega 3 PUFA (Omacor) 1 g/day has no effect on HRV is patients post AMI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089085     DOI: 10.1007/s10557-006-0295-z

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  14 in total

Review 1.  New approaches to therapy with omega-3 fatty acids.

Authors:  Puneet Kakar; Timothy Watson; Gregory Y H Lip
Journal:  Curr Atheroscler Rep       Date:  2008-02       Impact factor: 5.113

Review 2.  Electrophysiological mechanisms of the anti-arrhythmic effects of omega-3 fatty acids.

Authors:  Eric S Richardson; Paul A Iaizzo; Yong-Fu Xiao
Journal:  J Cardiovasc Transl Res       Date:  2010-12-02       Impact factor: 4.132

3.  Long-chain, n-3 fatty acids and physical activity--independent and interactive associations with cardiac autonomic control.

Authors:  Matthew P Harbaugh; Stephen B Manuck; J Richard Jennings; Sarah M Conklin; Jeffrey K Yao; Matthew F Muldoon
Journal:  Int J Cardiol       Date:  2012-06-16       Impact factor: 4.164

4.  Effect of dietary omega-3 fatty acids on the heart rate and the heart rate variability responses to myocardial ischemia or submaximal exercise.

Authors:  George E Billman; William S Harris
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-04-01       Impact factor: 4.733

Review 5.  Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

6.  Effects of omega-3 fatty acid supplementation on heart rate variability at rest and during acute stress in adults with moderate hypertriglyceridemia.

Authors:  Katherine A Sauder; Ann C Skulas-Ray; Tavis S Campbell; Jillian A Johnson; Penny M Kris-Etherton; Sheila G West
Journal:  Psychosom Med       Date:  2013-04-16       Impact factor: 4.312

7.  Effects of dietary omega-3 fatty acids on ventricular function in dogs with healed myocardial infarctions: in vivo and in vitro studies.

Authors:  George E Billman; Yoshinori Nishijima; Andriy E Belevych; Dmitry Terentyev; Ying Xu; Kaylan M Haizlip; Michelle M Monasky; Nitisha Hiranandani; William S Harris; Sandor Gyorke; Cynthia A Carnes; Paul M L Janssen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-22       Impact factor: 4.733

Review 8.  Impact of dietary fatty acids on cardiac arrhythmogenesis.

Authors:  Julie H Rennison; David R Van Wagoner
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-08

9.  Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease.

Authors:  Giacomo Levantesi; Maria Giuseppina Silletta; Roberto Marchioli
Journal:  J Multidiscip Healthc       Date:  2010-07-07

Review 10.  Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy.

Authors:  Jeetesh V Patel; Inessa Tracey; Elizabeth A Hughes; Gregory Y H Lip
Journal:  Vasc Health Risk Manag       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.